Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Renovo is a biopharmaceutical product company and is a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration. We aim to be first to market with a scar reduction pharmaceutical drug in the US and Europe to capitalise on this huge, unmet market need. Our pipeline includes one drug in phase 3 clinical development, two drugs in phase 2 clinical development and numerous pre-clinical candidates.

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom.

The BTG Specialty Pharmaceuticals business develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings, including the clinically proven and leading products CroFab®, DigiFab®, and Voraxaze®.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Konkuk University Industry-Academic Cooperation Foundation increases the competitiveness of industries by linking company and university.

Pharmaxis Ltd (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® forthe assessment of asthma issold in key international markets. Its product Bronchitol® for cystic fibrosis is recently launched in Europe and Australia and its development pipeline of productsincludes, Bronchitol for bronchiectasis, PXS64 forthe treatment of lung fibrosis, ASM8 for asthma and PXS4728 for fibrotic disease. Pharmaxisislisted on the Australian Securities Exchange (symbol PXS). The company’s head office and manufacturing facilities are located in Sydney.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. After World War II, Ethicon's market share in surgical sutures rose from 15% to 70% worldwide. In the United States, the market share is approximately 80%.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Universitätsklinikum Hamburg-Eppendorf operates as a university hospital. It offers basic and specialized healthcare services, and it offers medical students an opportunity to practice their profession. The hospital was founded on the 19th of May, 1889 and is located in Hamburg, Germany.

Adelaide Research & Innovation Pty Ltd., part of University of Adelaide, is a company headquartered in Adelaide, Australia, that provides analytical research services. Robert Chalmers is the current CEO of the firm.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

greenovation Biotech has developed an innovative technology for the production of proteins using moss cells. The “moss bioreactor“, is a safe and cost-effective production platform for biopharmaceuticals with special characteristics that improve the activity of therapeutic proteins, such as antibodies.